Ivabradine improves heart rate variability in patients with nonischemic dilated cardiomyopathy

Arquivos Brasileiros de Cardiologia

Volumn 103, Issue 4, 2014, Pages 308-314

  Kurtoglu, Ertugrul ^a   Balta, Sevket ^b   Karakus, Yasin ^a   Yasar, Erdogan ^a   Cuglan, Bilal ^a   Kaplan, Ozgur ^a   Gozubuyuk, Gokhan ^a  

^a MALATYA STATE HOSPITAL   (Turkey)

^b ESKISEHIR MILITARY HOSPITAL   (Turkey)

Author keywords

Anti arrhythmia agents therapeutic use; Cardiomyopathy; Dilated; Heart rate

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIAC GLYCOSIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IVABRADINE; BENZAZEPINE DERIVATIVE; CARDIOTONIC AGENT;

AGED; ARTICLE; BODY MASS; BRADYCARDIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR PARAMETERS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAINTENANCE DRUG DOSE; MALE; NEW YORK HEART ASSOCIATION CLASS; NONISCHEMIC CARDIOMYOPATHY; PARASYMPATHETIC TONE; RR INTERVAL; SMOKING; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; CARDIOMYOPATHY, DILATED; DRUG EFFECTS; ELECTROCARDIOGRAPHY; EVALUATION STUDY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BENZAZEPINES; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART FAILURE; HEART RATE; HUMANS; MALE; MIDDLE AGED; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84907463060     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20140109     Document Type: Article

References (40)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847.
2. Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-6.
3. Camm AJ, Lau CP. Electrophysiological effects of a single intravenous administration of ivabradine (S 16257) in adult patients with normal baseline electrophysiology. Drugs. 2003;4(2):83-9.
4. Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149-55.
5. Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282-8.
6. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet. 2010;376(9744):875-85.
7. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation. 1996;93(5):1043-65.
8. Pitzalis MV, Mastropasqua F, Massari F, Forleo C, Di Maggio M, Passantino A, et al. Short and long-term reproducibility of time and frequency domain heart rate variability measurements in normal subjects. Cardiovasc Res. 1996;32(2):226-33.
9. Karcz M, Chojnowska L, Zareba W, Ruzyllo W. Prognostic significance of heart rate variability in dilated cardiomyopathy. Int J Cardiol. 2003;87(1):75-81.
10. Fauchier L, Babuty D, Cosnay P, Autret ML, Fauchier JP. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol. 1997;30(4):1009-14.
11. Binkley PF. Heart rate variability: two eras of investigation. J Card Fail. 1996;2(3):193-6.
12. Bilchick KC, Fetics B, Djoukeng R, Fisher SG, Fletcher RD, Singh SN, et al. Prognostic value of heart rate variability in chronic congestive heart failure (Veterans Affairs’ Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure). Am J Cardiol. 2002;90(1):24-8.
13. Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):4-15.
14. Tardif JC, Ponikowski P, Kahan T; ASSOCIATE investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. Int J Cardiol. 2013;168(2):789-94.
15. Picard MH, Adams D, Bierig SM, Dent JM, Douglas PS, Gillam LD, et al. American Society of Echocardiography recommendations for quality echocardiography laboratory operations. J Am Soc Echocardiogr. 2011;24(1):1-10.
16. Di Francesco D, Camm AJ. Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64(16):1757-65.
17. Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of ivabradine induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572(Pt 2):335-46.
18. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R; BEAUTIFUL Investigators. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J. 2009;30(19):2337-45.
19. Sarullo FM, Fazio G, Puccio D, Fasullo S, Paterna S, Novo S, et al. Impact of ‘’off-label’’ use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010;15(4):349-55.
20. Volterrani M, Cice G, Caminiti G, Vitale C, D’Isa S, Perrone Filardi P, et al. Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol. 2011;151(2):218-24.
21. Fasullo S, Cannizzaro S, Maringhini G, Ganci F, Giambanco F, Vitale G, et al. Comparison of ivabradine versus metoprolol in early phases of reperfused anterior myocardial infarction with impaired left ventricular function: preliminary findings. J Card Fail. 2009;15(10):856-63.
22. Tsuji H, Venditti FJ Jr, Manders ES, Evans JC, Larson MG, Feldman CL, et al. Reduced heart rate variability and mortality risk in an elderly cohort. The Framingham Heart Study. Circulation. 1994;90(2):878-83.
23. Doğru MT, Simşek V, Sahin O, Ozer N. Differences in autonomic activity in individuals with optimal, normal, and high-normal blood pressure levels. Turk Kardiyol Dern Ars. 2010;38(3):182-8.
24. Turker Y, Aslantas Y, Aydin Y, Demirin H, Kutlucan A, Tibilli H, et al. Heart rate variability and heart rate recovery in patients with type 1 diabetes mellitus. Acta Cardiol. 2013;68(2):145-50.
25. Shah SA, Kambur T, Chan C, Herrington DM, Liu K, Shah SJ. Relation of short‑term heart rate variability to incident heart failure (from the Multi‑Ethnic Study of Atherosclerosis). Am J Cardiol. 2013;112(4):533-40.
26. Coviello I, Pinnacchio G, Laurito M, Stazi A, Battipaglia I, Barone L, et al. Prognostic role of heart rate variability in patients with ST-segment elevation acute myocardial infarction treated by primary angioplasty. Cardiology. 2013;124(1):63-70.
27. Munjal S, Koval T, Muhammad R, Jin Y, Demmel V, Roethig HJ, et al. Heart rate variability increases with reductions in cigarette smoke exposure after 3 days. J Cardiovasc Pharmacol Ther. 2009;14(3):192-8.
28. Antelmi I, de Paula RS, Shinzato AR, Peres CA, Mansur AJ, Grupi CJ. Influence of age, gender, body mass index, and functional capacity on heart rate variability in a cohort of subjects without heart disease. Am J Cardiol. 2004;93(3):381-5.
29. Kurtoglu E, Akturk E, Korkmaz H, Atas H, Cuglan B, Pekdemir H. Impaired heart rate variability in patients with mitral annular calcification: an observational study. Anadolu Kardiyol Derg. 2013;13(7):668-74.
30. Aronson D, Burger AJ. Effect of beta-blockade on heart rate variability in decompensated heart failure. Int J Cardiol. 2001;79(1):31-9.
31. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005;11(9):693-9.
32. Jansson K, Hagerman I, Ostlund R, Karlberg KE, Nylander E, Nyquist O, et al. The effects of metoprolol and captopril on heart rate variability in patients with idiopathic dilated cardiomyopathy. Clin Cardiol. 1999;22(6):397-402.
33. Tambara K, Fujita M, Sumita Y, Miyamoto S, Sekiguchi H, Eiho S, et al. Beneficial effect of candesartan treatment on cardiac autonomic nervous activity in patients with chronic heart failure: simultaneous recording of ambulatory electrocardiogram and posture. Clin Cardiol. 2004;27(5):300-3.
34. De Tommasi E, Iacoviello M, Romito R, Ceconi C, Guida P, Massari F, et al. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. Am Heart J. 2003;146(5):E17.
35. Yee KM, Pringle SD, Struthers AD. Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol. 2001;37(7):1800-7.
36. Gislason GH, Rasmussen V, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27(10):1153-8.
37. Follath F. Challenging the dogma of high target doses in the treatment of heart failure: is more always better? Arch Cardiovasc Dis. 2009;102(11):785-9.
38. Busseuil D, Shi Y, Mecteau M, Brand G, Gillis MA, Thorin E, et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology. 2010;117(3):234-42.
39. Tardif JC, O’Meara E, Komajda M, Böhm M, Borer JS, Ford I, et al; SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011;32(20):2507-15.
40. Drouin A, Gendron ME, Thorin E, Gillis MA, Mahlberg-Gaudin F, Tardif JC. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol. 2008;154(4):749-57.